Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer

Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer

Submitted by admin on January 28, 2025 - 10:40am
Source: 
BioPharma Dive
News Tags: 
AstraZeneca
Daiichi Sankyo
Enhertu
HER2-low breast cancer
FDA
Headline: 
Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer
snippet: 

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ahead of chemo in a variety of tumors.

Do Not Allow Advertisers to Use My Personal information